Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?

Tytuł:
Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
Autorzy:
Krzyżanowska N; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Krawczyk P; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Wojas-Krawczyk K; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Kucharczyk T; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Milanowski J; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Źródło:
Cells [Cells] 2022 Oct 18; Vol. 11 (20). Date of Electronic Publication: 2022 Oct 18.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/therapy
Immunotherapy*/methods
Lung Neoplasms*/therapy
Molecular Targeted Therapy*
Female ; Humans ; Male ; Antibodies, Monoclonal/therapeutic use ; B7-H1 Antigen/genetics ; Immune Checkpoint Inhibitors ; Protein Kinase Inhibitors/therapeutic use
References:
Clin Cancer Res. 2017 Jun 15;23(12):3012-3024. (PMID: 28039262)
Ann Oncol. 2017 Jan 1;28(1):75-82. (PMID: 27687306)
N Engl J Med. 2021 Jun 24;384(25):2371-2381. (PMID: 34096690)
J Clin Oncol. 2013 Nov 1;31(31):3987-96. (PMID: 24101047)
Lancet Oncol. 2018 Apr;19(4):521-536. (PMID: 29545095)
N Engl J Med. 2015 Oct 22;373(17):1627-39. (PMID: 26412456)
Front Immunol. 2017 Nov 28;8:1679. (PMID: 29234329)
Clin Cancer Res. 2022 Jan 15;28(2):249-254. (PMID: 34344795)
Surg Pathol Clin. 2020 Mar;13(1):17-33. (PMID: 32005431)
PLoS One. 2014 Jun 30;9(6):e101354. (PMID: 24979348)
Clin Lung Cancer. 2021 Jul;22(4):253-259. (PMID: 33582070)
Cancer Metastasis Rev. 2020 Dec;39(4):1159-1177. (PMID: 32548736)
BMC Pulm Med. 2021 Apr 17;21(1):125. (PMID: 33865348)
Oncologist. 2018 Jun;23(6):740-745. (PMID: 29438093)
Ann Oncol. 2019 Aug 1;30(8):1321-1328. (PMID: 31125062)
Lung Cancer. 2018 Oct;124:117-124. (PMID: 30268448)
Sci Rep. 2022 Feb 28;12(1):3319. (PMID: 35228655)
J Thorac Oncol. 2019 Mar;14(3):553-559. (PMID: 30529597)
JTO Clin Res Rep. 2021 May 18;2(7):100187. (PMID: 34590036)
Cancer Discov. 2018 Jul;8(7):822-835. (PMID: 29773717)
Clin Cancer Res. 2016 Sep 15;22(18):4585-93. (PMID: 27225694)
Oncoimmunology. 2015 Dec 21;5(3):e1094598. (PMID: 27141355)
Front Cell Dev Biol. 2021 Sep 28;9:745859. (PMID: 34660603)
Lancet. 2016 Apr 9;387(10027):1540-1550. (PMID: 26712084)
Diagn Pathol. 2020 Jan 30;15(1):6. (PMID: 32000815)
Lung Cancer (Auckl). 2021 Mar 25;12:21-34. (PMID: 33790679)
J Thorac Oncol. 2020 Apr;15(4):628-636. (PMID: 31945494)
Front Immunol. 2019 Jun 20;10:1398. (PMID: 31281318)
Front Oncol. 2022 Apr 06;12:863461. (PMID: 35463328)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
N Engl J Med. 2022 Jul 14;387(2):120-131. (PMID: 35658005)
Ann Oncol. 2019 May 1;30(5):839-844. (PMID: 30847464)
Ann Oncol. 2018 Oct 1;29(10):2085-2091. (PMID: 30165371)
Nat Rev Cancer. 2019 Sep;19(9):495-509. (PMID: 31406302)
Front Oncol. 2021 Jan 12;10:586596. (PMID: 33511076)
Cancer Discov. 2021 Nov;11(11):2828-2845. (PMID: 34230008)
Lancet. 2017 Jan 21;389(10066):255-265. (PMID: 27979383)
J Thorac Oncol. 2018 Aug;13(8):1138-1145. (PMID: 29874546)
Crit Rev Oncol Hematol. 2020 Dec;156:103119. (PMID: 33053439)
ESMO Open. 2020 Oct;5(5):e000799. (PMID: 33097651)
Curr Oncol Rep. 2021 Jun 14;23(8):94. (PMID: 34125313)
Clin Cancer Res. 2020 Apr 1;26(7):1624-1632. (PMID: 31871300)
Cancer Treat Rev. 2020 Apr;85:101978. (PMID: 32062493)
CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946)
Ann Oncol. 2020 Mar;31(3):404-411. (PMID: 32067682)
Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. (PMID: 29764856)
Clin Lung Cancer. 2020 May;21(3):e216-e228. (PMID: 32014348)
J Thorac Oncol. 2015 Jun;10(6):910-23. (PMID: 25658629)
J Thorac Oncol. 2019 Jan;14(1):135-140. (PMID: 30205166)
Ann Pharmacother. 2022 Jun 2;:10600280221098398. (PMID: 35652704)
J Adv Pract Oncol. 2020 May-Jun;11(4):418-423. (PMID: 33604102)
Cancer Discov. 2015 Aug;5(8):860-77. (PMID: 26069186)
Oncoimmunology. 2017 Jul 26;6(11):e1356145. (PMID: 29147605)
J Thorac Oncol. 2018 Aug;13(8):1128-1137. (PMID: 29723688)
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii5-viii15. (PMID: 31738427)
JAMA. 2019 Apr 9;321(14):1391-1399. (PMID: 30964529)
Clin Cancer Res. 2022 Apr 14;28(8):1482-1486. (PMID: 34903582)
Cancer Discov. 2013 Dec;3(12):1355-63. (PMID: 24078774)
Cancers (Basel). 2021 Sep 01;13(17):. (PMID: 34503226)
J Thorac Oncol. 2021 Nov;16(11):1952-1958. (PMID: 34245914)
Contributed Indexing:
Keywords: immune checkpoint inhibitor; immunotherapy; molecularly targeted therapy; non-small-cell lung cancer; oncogenic driver alteration
Substance Nomenclature:
0 (Antibodies, Monoclonal)
0 (B7-H1 Antigen)
0 (Immune Checkpoint Inhibitors)
0 (Protein Kinase Inhibitors)
Entry Date(s):
Date Created: 20221027 Date Completed: 20221104 Latest Revision: 20221206
Update Code:
20240105
PubMed Central ID:
PMC9600960
DOI:
10.3390/cells11203280
PMID:
36291146
Czasopismo naukowe
For many years, researchers have been trying to develop the most effective ways to fight lung cancer, which is the cause of the largest number of cancer-related deaths among men and women worldwide. The most advanced treatments for nearly all non-small-cell lung cancer (NSCLC) types include immunotherapy with immune checkpoint inhibitors (ICIs), mainly anti-programmed death 1/anti-programmed death ligand 1 monoclonal antibodies (anti-PD-1/PD-L1 mAbs) in monotherapy or in combination with other strategies. Despite significant advances, long survival is not achievable in most cases, so new solutions are constantly being sought. One of the questions raised by oncologists is the efficacy of ICIs in patients with molecular driver alterations, especially when the possibilities of using molecularly targeted therapies are exhausted (e.g., due to resistance to tyrosine kinase inhibitors). There are studies investigating this problem, but it is still poorly described. Among probable immunotherapy' failures reasons, low immunogenicity of tumors with one driver mutation is listed. Nevertheless, in some cases, the therapy is efficient, and more research is required to establish the management of NSCLC patients with oncogenic driver abnormalities. The aim of this article is to review current discoveries in this matter.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies